Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phototoxic Potential of Faldaprevir in Healthy Subjects
NCT02114671Phase 1Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of faldaprevir in hepatitis C (HCV) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with drug related adverse events at 17 days, Change in minimum erythema dose (MED) at each wavelength tested at 7 days and 1 more. Planned start Apr 2014; status: withdrawn.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02114671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114671.